权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Integrating NK and DC into Cancer Therapy

将 NK 和 DC 整合到癌症治疗中

基本信息

批准号：
7499879
负责人：
MICHAEL T LOTZE
金额：
$ 10.74万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-07-06 至 2010-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7499879
关键词：
Acute Adam11 gene Adjuvant Adjuvant Therapy Adoptive Transfer Affinity American Society of Clinical Oncology Andro-Diane Animal Model Antigens Apoptosis Apoptotic Appearance Arsenic Attention Automobile Driving Bacteria Benign Prostatic Hypertrophy Bioinformatics Biological Biological Assay Biological Markers Biological Response Modifier Therapy Biology Biosensor Biostatistics Core Biotechnology Blood Blood Tests Breast Carcinoma CCL17 gene CCL18 gene CCL2 gene CCL22 gene CCL8 gene CD80 gene Cancer Biology Cancer Control Cancer Model Cancer Patient Cancer Therapy Evaluation Program Caring Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine Cell Therapy Cell physiology Cells Cellular Assay Cessation of life Charge China Chronic Chronic Disease Clinic Clinical Clinical Trials Colorectal Cancer Combined Modality Therapy Complex Containment Cross Presentation Cytokine Network Pathway Cytotoxic agent Data Dendritic Cells Depth Development Diagnosis Discrimination Disease Disease regression Distant Dose Early Diagnosis Effector Cell Elements End Point Endothelial Cells Engineering Environment Esophagitis Evaluation Event Extramural Activities Failure Family Family member Fibroblasts Frequencies Genes Genomics Glioma Goals Granzyme Head and neck structure Healed Hepatitis Human Human Genome Human Papillomavirus IL8 gene Image Immune Immune response Immunity Immunologics In Situ In Vitro Individual Inflammation Inflammatory Inflammatory Response Injection of therapeutic agent Injury Ink Interferon-alpha Interleukin-1 Interleukin-10 Interleukin-12 Interleukin-13 Interleukin-16 Interleukin-17 Interleukin-2 Interleukin-4 Interleukin-6 Intralymphatic Injections Investigational Therapies Ions Laboratories Large Intestine Carcinoma Learning Left Lymphokines MHC antigen Malignant Lymph Node Neoplasm Malignant Neoplasms Malignant neoplasm of ovary Malignant neoplasm of pancreas Malignant neoplasm of prostate Mass Spectrum Analysis Measures Mediating Mediator of activation protein Memory Methods Minor Modeling Modification Molecular Monitor Mus Mutation Natural Killer Cells Nature Necrosis Neoplasm Metastasis Neoplasms Nitric Oxide Nuclear Numbers Outcome Patients Pattern Peptide/MHC Complex Peptides Peripheral Blood Mononuclear Cell Pharmaceutical Preparations Pharmacologic Substance Phase Phenotype Physiologic pulse Play Pre-Clinical Model Primary carcinoma of the liver cells Principal Investigator Production Program Review Group Prostaglandins Proteins Proteomics Publishing Pulse taking Quality Control Randomized Recruitment Activity Rectal Cancer Recurrence Reporting Role Safety Scientist Seminal Sensitivity and Specificity Serum Serum Proteins Shared Paranoid Disorder Signal Transduction Site Smoke Societies Solutions Specificity Specimen Staging Standards of Weights and Measures Stimulus Supercomputing Suppressor-Effector T-Lymphocytes Surface System T-Lymphocyte TNF gene Techniques Technology Testing Tetradecanoylphorbol Acetate Therapeutic Time Tissues Today Toll-like receptors Toxic effect Toxin Treatment Protocols Treatment-Related Cancer Tumor Antigens Tumor Expansion Tumor Necrosis Factor Ligand Superfamily Member 6 Twin Multiple Birth United States Food and Drug Administration Universities University of Pittsburgh Cancer Institute Vaccines Virginia Virus Virus Diseases Week base biochip cancer care cancer therapy carcinogenesis chlorambucil/dactinomycin/methotrexate protocol contextual factors cost cost effective cytokine design expectation experience falls feeding healing human study improved in vivo insight interest interleukin-23 irradiation irritation kidney cell macrophage malignant breast neoplasm melanoma member neoplastic neoplastic cell neutrophil novel novel strategies outcome forecast perforin peripheral blood programs prospective response success surface enhanced laser desorption ionization theories tumor tumor growth tumor progression vaccination strategy

项目摘要

DCs, NK and T-cells found within human tumors have been associated with an improved prognosis in almost every tumor type examined. Indeed their recruitment may be modified during development of the chronic inflammatory response. Cancer arises in the setting of chronic inflammation - inducing an acute inflammatory response to elicit new T-cells capable of mediating sustained and more effective antitumor activity is the central premise of this proposal. Integrating NK and DC into Cancer Therapy with direct injection into tumor or coincubated ex vivo with tumor or tumor antigens administered as an immunogen, will result in tumor destruction and elicit an effective adaptive immune response. The identification of critical biomarkers and surrogates using modern proteomic, genomic, and cellomic strategies will be integrated into all projects as a means to test these strategies more readily in early disease. We hypothesize that by directing NK and DC to rumor sites in situ, that we can enhance regression of established local disease, promoting a more effective systemic immunity to tumor. Coordinate signaling is necessary between NK and DCs to initiate optimal TH1 polarization, subsequently driving an effective adaptive T-cell response to cancer. Indeed, after two decades of NKJANK/LAK adoptive transfer and several years of experience with over 1000 patients receiving DCs, it is becoming apparent that cooperative interactions between NK and DC will be necessary to modify the established immune response to cancer. We will investigate this in four projects: Project I. Initiating the Adaptive Immune Response to Cancer; Project II. NK cells induce DCl-mediated anti-rumor immunity, and Project IlL IL-1 Homolognes Promote the Acute Inflammatory Response to Melanoma. Development of these three projects will be supported by three cores: A) Administrative, Bioinformatics and Biostatistics Core B) Imaging Core, and C) Proteomics Core. Project I will enable further development of the clinical trials proposed in patients with melanoma and colorectal cancer who will be evaluated and treated in Projects II and III. Evaluation of direct intralymphatic injection of NK matured DC 1 fed tumor antigen or lysates will be contrasted with strategies using direct intratumoral injection of NK and DC.

在人类肿瘤中发现的DC、NK和T细胞与几乎所有癌症患者的预后改善相关。每种肿瘤类型都检查过。事实上，它们的募集可能在慢性疾病的发展过程中被改变。炎症反应。癌症发生在慢性炎症的背景下-诱导急性炎症性疾病。诱导能够介导持续和更有效的抗肿瘤活性的新T细胞的反应是核心这一提议的前提。将NK和DC整合到癌症治疗中，直接注射到肿瘤中或与作为免疫原施用的肿瘤或肿瘤抗原离体共孵育，将导致肿瘤破坏并引发有效的适应性免疫反应。关键生物标志物的鉴定，使用现代蛋白质组学、基因组学和细胞组学策略的替代物将作为一种这意味着更容易在早期疾病中测试这些策略。我们假设通过引导NK和DC 谣言网站在原地，我们可以加强既定的局部疾病消退，促进更有效的对肿瘤的全身免疫。NK和DC之间的协调信号传导是启动最佳TH 1所必需的极化，随后驱动有效的适应性T细胞对癌症的反应。事实上，经过二十年的 NKJANK/LAK过继转移和超过1000例接受DC的患者的多年经验，越来越明显的是，NK和DC之间的合作相互作用将是必要的，以修改对癌症的免疫反应。我们将在四个项目中对此进行研究：项目I。发起癌症的适应性免疫反应;项目II。NK细胞诱导DCI介导的抗肿瘤免疫， IL-1同系物促进对黑色素瘤的急性炎症反应。发展这三个项目将得到三个核心的支持：A）行政、生物信息学和生物统计学核心 B）成像核心，和C）蛋白质组学核心。项目I将促进临床试验的进一步发展拟用于将在项目II中接受评估和治疗的黑色素瘤和结直肠癌患者，三.将评估直接淋巴内注射NK成熟DC 1饲养的肿瘤抗原或裂解物的效果。与直接瘤内注射NK和DC的策略相比。